Adamantanes might be protective from COVID-19 in patients with neurological diseases: multiple sclerosis, parkinsonism and cognitive impairment

•We report on a questionnaire-based study performed to assess severity of COVID-19 in patients suffering from multiple sclerosis, Parkinson's disease and cognitive impairment.•All patients were receiving treatments with either amantadine or memantine on stable registered doses.•In all patients...

Full description

Saved in:

Bibliographic Details
Published in:	Multiple sclerosis and related disorders Vol. 42; p. 102163
Main Authors:	Rejdak, Konrad, Grieb, Paweł
Format:	Journal Article
Language:	English
Published:	Netherlands Elsevier B.V 01.07.2020
Subjects:	Adamantane - therapeutic use Adamantanes Adult Aged Aged, 80 and over Amantadine Amantadine - therapeutic use Asymptomatic Infections Betacoronavirus Case Report Cognitive Dysfunction - complications Cognitive Dysfunction - drug therapy Cognitive impairment Coronavirus Infections - complications Coronavirus Infections - physiopathology COVID-19 Dopamine Agents - therapeutic use Female Humans Male Memantine Memantine - therapeutic use Middle Aged Multiple sclerosis Multiple Sclerosis - complications Multiple Sclerosis - drug therapy Neurology Pandemics Parkinson Disease - complications Parkinson Disease - drug therapy Pneumonia, Viral - complications Pneumonia, Viral - physiopathology Protection Protective Factors SARS-CoV-2 Severity of Illness Index COVID-19 Adamantanes Amantadine Multiple sclerosis SARS-CoV-2 Memantine PD Protection Cognitive impairment
ISSN:	2211-0348, 2211-0356, 2211-0356
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!